Understanding how malaria parasites become resistant to drugs
Malaria parasites cause approximately 240 million infections each year, which results in approximately 608,000 deaths annually. There are drugs that help treat malaria infection and the current best treatments are artemisinin-based combination therapies.
Unfortunately, parasites are developing resistance to artemisinin. It is known that specific mutations in the Kelch-13 gene underpin artemisinin resistance phenotypes and one specific mutation in this gene, C580Y, has been linked with treatment failure throughout Southeast Asia.
Most of the global malaria disease burden is experienced by West Africa, where fortunately artemisinin resistance is not yet widespread and artemisinin-combination therapies remain effective treatment options.
Alarmingly however, novel African-specific mutations in Kelch-13 are being detected in East Africa and are expected to spread to West Africa in the next 5-7 years. As these mutations are different from those that have been well-defined in Southeast Asia, it is not yet known what effect they will have on artemisinin resistance.
This project is open to students
State-of-the-art molecular biology techniques
The project will seek to understand how these novel mutations will affect malaria parasites from West Africa. It will involve inserting these point mutations into the Kelch-13 gene into parasites of Africa origin and assessing if they engender artemisinin resistance.
This project will involve state-of-the-art molecular biology techniques with a variety of plate- and microscopy-based phenotypic assays. It will have a real-world impact as it will help predict the effect of these mutations in currently circulating parasite populations.
Open to
- Honours
- Masters by research
- PhD
Vacancies
6
Supervisors
Project contacts

Associate Professor Paul Gilson
Deputy Discipline Head, Life Sciences; Co-Head Malaria Virulence, Drug Discovery and Resistance; Head of Burnet Cell Imaging Facility

Dr Hayley Bullen
Co-Head Malaria Virulence, Drug Discovery and Resistance
Project team

Dr Hayley Bullen
Co-Head Malaria Virulence, Drug Discovery and Resistance

Associate Professor Paul Gilson
Deputy Discipline Head, Life Sciences; Co-Head Malaria Virulence, Drug Discovery and Resistance; Head of Burnet Cell Imaging Facility

Rachael Yong
PhD Student
More student projects
View 62 more
Young people’s health in Australia: statistics from the Sex, Drugs and Rock ‘n’ Roll survey
Every year, we survey young people about their sexual health, drug use, mental health and wellbeing. That data informs public health policies and programs.

Germinal centre organoids to investigate human immune response to infection and vaccination
We're using germinal centre organoid models to investigate human immune development to malaria parasites and malaria vaccines.

Impact of malaria and other host factors on COVID-19 immune responses following infection and vaccination
Understanding immune development to the COVID-19 virus (SARS-CoV-2) in areas of high malaria transmission will inform future COVID-19 control strategies and underlying immune development.